BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...structure until after absorption. Freund is managing director of Skyline Ventures. He was chairman of XenoPort Inc....
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...LAS41008 , a dimethyl fumarate that targets NFE2L2, in Phase III testing to treat psoriasis. XenoPort Inc....
BioCentury | May 30, 2016
Company News

XenoPort, Arbor Pharmaceuticals deal

...to XenoPort’s close of $4.40 on May 20, the day before the deal was announced. XenoPort...
...which is approved in the U.S. to treat restless legs syndrome and manage postherpetic neuralgia. XenoPort...
...in 2015 sales of the drug. The companies expect the deal to close next quarter. XenoPort Inc....
BioCentury | May 24, 2016
Company News

Arbor acquiring XenoPort

...Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or...
...approved in the U.S. to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia. XenoPort...
...million in 2015 sales of the drug. The acquisition price is a 60% premium to XenoPort's...
BioCentury | Apr 4, 2016
Company News

XenoPort, Dr. Reddy’s Laboratories Ltd. deal

...XenoPort granted Dr. Reddy’s exclusive, U.S. rights to develop and commercialize XP23829 . XenoPort will receive...
...in regulatory milestones and $250 million in commercial milestones, plus royalties up to the mid-teens. XenoPort...
...trial to treat moderate to severe chronic plaque-type psoriasis. XenoPort declined to disclose additional details. XenoPort Inc....
BioCentury | Mar 29, 2016
Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

...induces and activates the nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2 ; NRF2 ) pathway. XenoPort...
...in regulatory milestones and $250 million in commercial milestones, plus royalties up to the mid-teens. XenoPort...
...also will receive $2.5 million upon the transfer of clinical trial materials to Dr. Reddy%27s. XenoPort...
BioCentury | Jan 4, 2016
Finance

Big band swing

...9-mo op loss ended 9/30 10/1/15 XenoPort Inc. (NASDAQ:XNPT) 14% to 155 $152.4 1.71 9/30/15 $66.7 XenoPort...
BioCentury | Oct 12, 2015
Clinical News

XP23829: Development discontinued

...the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort...
...approved in the U.S. to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia. XenoPort Inc....
BioCentury | Oct 12, 2015
Company News

XenoPort neurology, autoimmune news

...Alcoholism (NIAAA) is conducting a Phase II trial of Horizant to treat alcohol use disorder. XenoPort...
...Tokyo, Japan) markets the transported prodrug of gabapentin in Japan as Regnite . In September, XenoPort...
...30, XenoPort had $170.4 million in cash and a six-month operating loss of $43.5 million. XenoPort Inc....
BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...MS). Almirall S.A. has LAS41008 , dimethyl fumarate, in Phase III testing to treat psoriasis. XenoPort Inc....
Items per page:
1 - 10 of 388
BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...structure until after absorption. Freund is managing director of Skyline Ventures. He was chairman of XenoPort Inc....
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...LAS41008 , a dimethyl fumarate that targets NFE2L2, in Phase III testing to treat psoriasis. XenoPort Inc....
BioCentury | May 30, 2016
Company News

XenoPort, Arbor Pharmaceuticals deal

...to XenoPort’s close of $4.40 on May 20, the day before the deal was announced. XenoPort...
...which is approved in the U.S. to treat restless legs syndrome and manage postherpetic neuralgia. XenoPort...
...in 2015 sales of the drug. The companies expect the deal to close next quarter. XenoPort Inc....
BioCentury | May 24, 2016
Company News

Arbor acquiring XenoPort

...Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or...
...approved in the U.S. to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia. XenoPort...
...million in 2015 sales of the drug. The acquisition price is a 60% premium to XenoPort's...
BioCentury | Apr 4, 2016
Company News

XenoPort, Dr. Reddy’s Laboratories Ltd. deal

...XenoPort granted Dr. Reddy’s exclusive, U.S. rights to develop and commercialize XP23829 . XenoPort will receive...
...in regulatory milestones and $250 million in commercial milestones, plus royalties up to the mid-teens. XenoPort...
...trial to treat moderate to severe chronic plaque-type psoriasis. XenoPort declined to disclose additional details. XenoPort Inc....
BioCentury | Mar 29, 2016
Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

...induces and activates the nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2 ; NRF2 ) pathway. XenoPort...
...in regulatory milestones and $250 million in commercial milestones, plus royalties up to the mid-teens. XenoPort...
...also will receive $2.5 million upon the transfer of clinical trial materials to Dr. Reddy%27s. XenoPort...
BioCentury | Jan 4, 2016
Finance

Big band swing

...9-mo op loss ended 9/30 10/1/15 XenoPort Inc. (NASDAQ:XNPT) 14% to 155 $152.4 1.71 9/30/15 $66.7 XenoPort...
BioCentury | Oct 12, 2015
Clinical News

XP23829: Development discontinued

...the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort...
...approved in the U.S. to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia. XenoPort Inc....
BioCentury | Oct 12, 2015
Company News

XenoPort neurology, autoimmune news

...Alcoholism (NIAAA) is conducting a Phase II trial of Horizant to treat alcohol use disorder. XenoPort...
...Tokyo, Japan) markets the transported prodrug of gabapentin in Japan as Regnite . In September, XenoPort...
...30, XenoPort had $170.4 million in cash and a six-month operating loss of $43.5 million. XenoPort Inc....
BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...MS). Almirall S.A. has LAS41008 , dimethyl fumarate, in Phase III testing to treat psoriasis. XenoPort Inc....
Items per page:
1 - 10 of 388